Your browser is no longer supported. Please, upgrade your browser.
Settings
XENT [NASD]
Intersect ENT, Inc.
Index- P/E- EPS (ttm)-2.07 Insider Own1.00% Shs Outstand33.19M Perf Week-0.44%
Market Cap907.91M Forward P/E- EPS next Y-1.32 Insider Trans0.00% Shs Float31.14M Perf Month-0.51%
Income-68.30M PEG- EPS next Q-0.43 Inst Own89.10% Short Float4.60% Perf Quarter41.27%
Sales102.60M P/S8.85 EPS this Y-61.90% Inst Trans-1.06% Short Ratio1.71 Perf Half Y39.03%
Book/sh1.25 P/B21.69 EPS next Y25.80% ROA-33.60% Target Price25.21 Perf Year58.45%
Cash/sh1.73 P/C15.71 EPS next 5Y7.60% ROE-112.80% 52W Range14.68 - 28.17 Perf YTD18.38%
Dividend- P/FCF- EPS past 5Y-16.80% ROI-51.50% 52W High-3.76% Beta1.57
Dividend %- Quick Ratio1.70 Sales past 5Y5.50% Gross Margin67.50% 52W Low84.67% ATR0.17
Employees406 Current Ratio2.00 Sales Q/Q178.60% Oper. Margin-61.80% RSI (14)50.85 Volatility0.44% 0.60%
OptionableYes Debt/Eq1.53 EPS Q/Q29.50% Profit Margin-66.50% Rel Volume0.14 Prev Close27.16
ShortableYes LT Debt/Eq1.53 EarningsAug 06 BMO Payout- Avg Volume837.70K Price27.11
Recom3.10 SMA20-0.36% SMA50-0.89% SMA20020.70% Volume117,029 Change-0.18%
Aug-12-21Downgrade SVB Leerink Outperform → Mkt Perform $28.25
Jun-24-21Upgrade SVB Leerink Mkt Perform → Outperform $23
Jan-11-21Upgrade Canaccord Genuity Hold → Buy $25
Nov-19-20Upgrade BTIG Research Neutral → Buy $32
Oct-08-20Downgrade JP Morgan Overweight → Neutral $19
Aug-07-20Upgrade Guggenheim Neutral → Buy $30
Jun-24-20Initiated Oppenheimer Perform
May-12-20Downgrade Canaccord Genuity Buy → Hold
Apr-15-20Downgrade BofA/Merrill Buy → Underperform $28 → $10
Aug-02-19Downgrade Piper Jaffray Overweight → Neutral $30 → $17
Aug-02-19Downgrade Guggenheim Buy → Neutral
Jul-10-19Upgrade Northland Capital Under Perform → Market Perform $20
Jun-21-19Downgrade Berenberg Buy → Hold
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $29
May-07-19Downgrade Northland Capital Market Perform → Under Perform $28 → $20
Apr-20-18Initiated Berenberg Buy
Jan-02-18Upgrade JP Morgan Neutral → Overweight
May-31-17Downgrade Northland Capital Outperform → Market Perform
May-03-17Reiterated Wedbush Outperform $25 → $26
Dec-07-16Initiated Guggenheim Buy $20
Oct-04-21 04:39AM  
Oct-01-21 09:20PM  
Sep-24-21 06:44AM  
Sep-23-21 05:25PM  
Sep-21-21 11:06AM  
Sep-20-21 09:29AM  
Sep-17-21 09:00PM  
03:45AM  
Sep-15-21 04:00PM  
Sep-14-21 12:40PM  
09:06AM  
Sep-13-21 03:23PM  
11:15AM  
Sep-11-21 03:02PM  
Sep-09-21 04:32AM  
Sep-04-21 01:00PM  
12:05PM  
Sep-03-21 01:54PM  
Sep-01-21 11:51AM  
Aug-30-21 05:00PM  
12:34PM  
Aug-27-21 03:01PM  
Aug-26-21 12:39PM  
12:15PM  
Aug-24-21 01:29PM  
Aug-23-21 05:10PM  
10:10AM  
Aug-21-21 09:06AM  
Aug-20-21 02:36PM  
Aug-19-21 01:20PM  
10:07AM  
Aug-18-21 04:33PM  
Aug-16-21 11:00AM  
Aug-14-21 09:06AM  
Aug-13-21 01:55PM  
Aug-12-21 08:29PM  
12:15PM  
Aug-11-21 07:58AM  
Aug-10-21 07:09PM  
Aug-09-21 07:09PM  
02:47PM  
11:05AM  
09:00AM  
Aug-07-21 10:06AM  
09:03AM  
Aug-06-21 06:41PM  
04:31PM  
04:22PM  
01:59PM  
01:23PM  
12:45PM  
12:12PM  
08:35AM  
08:09AM  
07:32AM  
07:30AM  
07:15AM  
07:00AM  
07:00AM  
Jul-30-21 03:00PM  
Jul-26-21 07:00AM  
Jul-23-21 08:22AM  
08:00AM  
Jul-22-21 04:05PM  
Jun-29-21 06:05AM  
Jun-11-21 09:06AM  
Jun-09-21 11:30AM  
Jun-08-21 10:32AM  
May-24-21 08:56AM  
May-20-21 07:46AM  
May-11-21 07:50AM  
May-10-21 08:20AM  
07:36AM  
07:00AM  
06:45AM  
May-07-21 04:05PM  
May-04-21 07:00AM  
Apr-29-21 04:05PM  
07:00AM  
Apr-20-21 08:00AM  
Apr-08-21 11:30AM  
Apr-05-21 04:05PM  
Apr-01-21 08:37AM  
Mar-23-21 08:56AM  
Mar-17-21 09:18AM  
Mar-11-21 04:05PM  
Mar-10-21 08:30AM  
04:20AM  
Mar-09-21 08:35AM  
07:00AM  
05:30AM  
Mar-08-21 10:09AM  
07:00AM  
Mar-05-21 09:59AM  
Mar-03-21 05:10AM  
Mar-02-21 12:30PM  
Feb-23-21 04:05PM  
Feb-11-21 07:00AM  
Feb-01-21 04:05PM  
Jan-26-21 08:22AM  
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOLL FREDERIC HDirectorJan 19Option Exercise0.7212,5009,000260,961Feb 05 06:53 PM